Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 14,938 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive Disease Clear all
Completed Phase 1 Interventional

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

NCT01351103
View directory record Official record
Conditions
Pancreatic Cancer, BRAF Mutant Colorectal Cancer, Melanoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Cancer, Cervical Squamous Cell Cancer, Esophageal Squamous Cell Cancer, Lung Squamous Cell Cancer
Interventions
LGK974, PDR001
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 23, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Results available

Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus

NCT00474903
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Cancer
Interventions
acetylsalicylic acid, esomeprazole magnesium, placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 23, 2026, 10:51 AM EDT
Active, not recruiting No phase listed Observational

Evaluation of Improved Onboard Patient Imaging

NCT06187103
View directory record Official record
Conditions
Head and Neck Cancer, Breast Cancer, Upper Gastrointestinal Cancer, Lung Cancer, Pelvic Cancer
Interventions
HyperSight Imaging
Device
Lead sponsor
Varian, a Siemens Healthineers Company
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 23, 2026, 10:51 AM EDT
Recruiting Not applicable Interventional

Viome Nutritional Programs to Improve Clinical Outcomes for Gastrointestinal Conditions

NCT05465629
View directory record Official record
Conditions
Gastrointestinal Health
Interventions
VIOME Precision Nutrition Program, VIOME-designed condition-based supplements
Combination Product · Dietary Supplement
Lead sponsor
Viome
Industry
Eligibility
25 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 23, 2026, 10:51 AM EDT
Recruiting Phase 2 Interventional

Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk

NCT05028829
View directory record Official record
Conditions
Liver Fibroses, Cirrhosis
Interventions
Atorvastatin 20mg, Placebo
Drug
Lead sponsor
Raymond Chung
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
2
States / cities
Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 10:51 AM EDT
Completed Early Phase 1 Interventional

Treatment of Muscle Cramps in Patients With Liver Cirrhosis

NCT01495403
View directory record Official record
Conditions
Liver Cirrhosis, Muscle Cramps
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 23, 2026, 10:51 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

NCT02514473
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-809, Placebo, VX-770
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years to 11 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 23, 2026, 10:51 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Testing of a Navigation Intervention for Hepatitis C and HIV

NCT04499651
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus), Hepatitis C
Interventions
Navigation
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 23, 2026, 10:51 AM EDT
Withdrawn Phase 2 Interventional

Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl

NCT04713202
View directory record Official record
Conditions
Neuroendocrine Tumors, Carcinoid Syndrome, Diarrhea
Interventions
Telotristat ethyl, Peptide Receptor Radionuclide Therapy, Placebo
Drug · Other
Lead sponsor
Chandrikha Chandrasekhara
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 23, 2026, 10:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Outcomes Following Parafascicular Surgical Evacuation of Intracerebral Hemorrhage: A Pilot Study

NCT01971359
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Not listed
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 23, 2026, 10:51 AM EDT
Completed No phase listed Observational

Where Culture Meets Genetics: Exploring Latinas Causal Attributions of Breast and Colon Cancer and Models of Disease Inheritance

NCT02767986
View directory record Official record
Conditions
Colon Cancer, Breast Cancer
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 75 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 23, 2026, 10:51 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

NCT00394173
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea (IBS-D)
Interventions
DNK333, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
180 participants
Timeline
2006 – 2007
U.S. locations
37
States / cities
Tucson, Arizona • North Little Rock, Arkansas • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 23, 2026, 10:51 AM EDT
Not listed No phase listed Observational

Patient Registry: Radio Frequency Ablation of Barrett's Esophagus Using HALO System

NCT02033070
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Not listed
Lead sponsor
Ochsner Health System
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Kenner, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 23, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Results available

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

NCT03442569
View directory record Official record
Conditions
Colon Cancer
Interventions
Panitumumab, Nivolumab, Ipilimumab
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
5
States / cities
Tampa, Florida • Indianapolis, Indiana • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 23, 2026, 10:51 AM EDT
Completed Phase 1 Interventional

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

NCT04164069
View directory record Official record
Conditions
Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage II Colon Cancer, Stage II Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Esophageal Cancer, Pancreatic Cancer, Bile Duct Cancer, Gastric Cancer, Gall Bladder Cancer, Small Bowel Adenocarcinoma
Interventions
Bevacizumab, Dasatinib, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
Anne Noonan
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 23, 2026, 10:51 AM EDT
Active, not recruiting No phase listed Observational

Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)

NCT03460769
View directory record Official record
Conditions
Pancreatic Cancer, Chronic Pancreatitis, Diabetes Mellitus Type 3c
Interventions
Data Management and Monitoring
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years to 84 Years
Enrollment
775 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
10
States / cities
Los Angeles, California • Stanford, California • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 23, 2026, 10:51 AM EDT
Active, not recruiting Not applicable Interventional

Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid

NCT06910670
View directory record Official record
Conditions
Cholangiocarcinoma, Colorectal Cancer, Multiple Myeloma
Interventions
Standard developed materials, Genetics Advisor Decision Aid
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Results available

Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer

NCT03199274
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Yttrium-90 Microsphere Radioembolization, Perflutren Protein-Type A Microspheres, Dynamic Contrast-Enhanced Ultrasound Imaging
Procedure · Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 23, 2026, 10:51 AM EDT
Active, not recruiting Phase 2 Interventional

Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)

NCT06519097
View directory record Official record
Conditions
Neoplasm of Pancreas, IPMN, Pancreatic
Interventions
Vitamin E Delta Tocotrienol, Placebo
Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Tampa, Florida • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 23, 2026, 10:51 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

NCT03104413
View directory record Official record
Conditions
Crohn's Disease
Interventions
placebo for risankizumab IV, risankizumab SC, risankizumab IV
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 80 Years
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
114
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 23, 2026, 10:51 AM EDT
Completed Phase 1 Interventional

QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.

NCT03552718
View directory record Official record
Conditions
Colorectal Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Pancreatic Cancer, Liver Cancer
Interventions
YE-NEO-001
Biological
Lead sponsor
NantBioScience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 23, 2026, 10:51 AM EDT
Completed Phase 1Phase 2 Interventional

PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

NCT03543813
View directory record Official record
Conditions
Solid Tumor, Adult, Head and Neck Cancer, Non Small Cell Lung Cancer, Diffuse Large B Cell Lymphoma, Esophageal Cancer
Interventions
CX-2029
Drug
Lead sponsor
CytomX Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Encinitas, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 23, 2026, 10:51 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

NCT00104520
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI 75 mg two times a day (BID)/three times a day (TID), Placebo two times a day (BID)/three times a day (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
56
States / cities
Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2011 · Synced Oct 23, 2026, 10:51 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)

NCT00513682
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
Ultrase® MT20
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years to 11 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Ann Arbor, Michigan • Cleveland, Ohio • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 23, 2026, 10:51 AM EDT